How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Sell
28
SNN Quote, Financials, Valuation and Earnings
Last price:
$29.33
Seasonality move
:
0.77%
Day range:
$29.86 - $30.18
52-week range:
$23.69 - $31.72
Dividend yield:
2.5%
P/E ratio:
32.09x
P/S ratio:
2.26x
P/B ratio:
2.49x
Volume:
634.4K
Avg. volume:
1.1M
1-year change:
5.77%
Market cap:
$13.1B
Revenue:
$5.8B
EPS (TTM):
$0.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
$1.5B | -- | -- | -- | $33.15 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$11.2M | -$0.14 | -91.39% | -8.33% | $1.45 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
GSK
GSK PLC
|
$10.6B | $1.14 | 5.94% | 60.08% | $41.72 |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | -100% | -87.66% | $7.32 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
$30.04 | $33.15 | $13.1B | 32.09x | $0.46 | 2.5% | 2.26x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.28 | $1.45 | $74.5M | -- | $0.00 | 0% | 0.40x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$0.98 | $17.94 | $4.9M | -- | $0.00 | 0% | 1.02x |
|
GSK
GSK PLC
|
$38.29 | $41.72 | $77.8B | 19.86x | $0.43 | 4.18% | 1.97x |
|
MREO
Mereo BioPharma Group PLC
|
$1.72 | $7.32 | $273.5M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.05 | $104.00 | $278K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
37.25% | 0.651 | 29.11% | 1.21x |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.289 | 50.03% | 1.57x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.010 | -- | 1.20x |
|
GSK
GSK PLC
|
56.56% | -0.254 | 30.39% | 0.58x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.029 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -1.015 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
-- | -- | 4.91% | 7.88% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
GSK
GSK PLC
|
$7B | $2.8B | 10.19% | 23.08% | 30.2% | $877.6M |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
Smith & Nephew PLC vs. Competitors
-
Which has Higher Returns SNN or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -653.18%. Smith & Nephew PLC's return on equity of 7.88% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About SNN or ADAP?
Smith & Nephew PLC has a consensus price target of $33.15, signalling upside risk potential of 10.36%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.45 which suggests that it could grow by 416.46%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Smith & Nephew PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC1 2 0 ADAPAdaptimmune Therapeutics PLC2 4 0 -
Is SNN or ADAP More Risky?
Smith & Nephew PLC has a beta of 0.689, which suggesting that the stock is 31.073% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.923%.
-
Which is a Better Dividend Stock SNN or ADAP?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.5%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or ADAP?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Smith & Nephew PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 32.09x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 2.26x versus 0.40x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC2.26x 32.09x -- -- ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M
-
Which has Higher Returns SNN or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 7.88% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About SNN or BDRX?
Smith & Nephew PLC has a consensus price target of $33.15, signalling upside risk potential of 10.36%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1731.01%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Smith & Nephew PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC1 2 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is SNN or BDRX More Risky?
Smith & Nephew PLC has a beta of 0.689, which suggesting that the stock is 31.073% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.
-
Which is a Better Dividend Stock SNN or BDRX?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.5%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or BDRX?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than Biodexa Pharmaceuticals PLC's net income of --. Notably, Smith & Nephew PLC's price-to-earnings ratio is 32.09x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 2.26x versus 1.02x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC2.26x 32.09x -- -- BDRXBiodexa Pharmaceuticals PLC1.02x -- -- --
-
Which has Higher Returns SNN or GSK?
GSK PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of 21.61%. Smith & Nephew PLC's return on equity of 7.88% beat GSK PLC's return on equity of 23.08%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B GSKGSK PLC74.23% $0.99 $41.5B -
What do Analysts Say About SNN or GSK?
Smith & Nephew PLC has a consensus price target of $33.15, signalling upside risk potential of 10.36%. On the other hand GSK PLC has an analysts' consensus of $41.72 which suggests that it could grow by 8.96%. Given that Smith & Nephew PLC has higher upside potential than GSK PLC, analysts believe Smith & Nephew PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC1 2 0 GSKGSK PLC1 5 1 -
Is SNN or GSK More Risky?
Smith & Nephew PLC has a beta of 0.689, which suggesting that the stock is 31.073% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.644%.
-
Which is a Better Dividend Stock SNN or GSK?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.5%. GSK PLC offers a yield of 4.18% to investors and pays a quarterly dividend of $0.43 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or GSK?
Smith & Nephew PLC quarterly revenues are --, which are smaller than GSK PLC quarterly revenues of $9.5B. Smith & Nephew PLC's net income of -- is lower than GSK PLC's net income of $2B. Notably, Smith & Nephew PLC's price-to-earnings ratio is 32.09x while GSK PLC's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 2.26x versus 1.97x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC2.26x 32.09x -- -- GSKGSK PLC1.97x 19.86x $9.5B $2B
-
Which has Higher Returns SNN or MREO?
Mereo BioPharma Group PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 7.88% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About SNN or MREO?
Smith & Nephew PLC has a consensus price target of $33.15, signalling upside risk potential of 10.36%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.32 which suggests that it could grow by 325.84%. Given that Mereo BioPharma Group PLC has higher upside potential than Smith & Nephew PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC1 2 0 MREOMereo BioPharma Group PLC6 0 0 -
Is SNN or MREO More Risky?
Smith & Nephew PLC has a beta of 0.689, which suggesting that the stock is 31.073% less volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.683%.
-
Which is a Better Dividend Stock SNN or MREO?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.5%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or MREO?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 32.09x while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 2.26x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC2.26x 32.09x -- -- MREOMereo BioPharma Group PLC-- -- -- -$12.9M
-
Which has Higher Returns SNN or NCNA?
NuCana PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 7.88% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About SNN or NCNA?
Smith & Nephew PLC has a consensus price target of $33.15, signalling upside risk potential of 10.36%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 226479.52%. Given that NuCana PLC has higher upside potential than Smith & Nephew PLC, analysts believe NuCana PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC1 2 0 NCNANuCana PLC0 1 0 -
Is SNN or NCNA More Risky?
Smith & Nephew PLC has a beta of 0.689, which suggesting that the stock is 31.073% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.
-
Which is a Better Dividend Stock SNN or NCNA?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.5%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or NCNA?
Smith & Nephew PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than NuCana PLC's net income of -$3.1M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 32.09x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 2.26x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC2.26x 32.09x -- -- NCNANuCana PLC-- -- -- -$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
77
VBTX alert for Jul 15
Veritex Holdings [VBTX] is down 3.26% over the past day.
Buy
72
MNPR alert for Jul 15
Monopar Therapeutics [MNPR] is down 8.6% over the past day.
Buy
56
NBIS alert for Jul 15
Nebius Group NV [NBIS] is up 2.98% over the past day.
